• ALX Oncology highlighted exploratory results already presented at ESMO Breast Cancer 2026 from its Phase 1b/2 study of evorpacept with Jazz Pharmaceuticals’ zanidatamab in heavily pretreated HER2-positive metastatic breast cancer.
• Analyses indicated responses were more durable in patients whose tumors showed high CD47 expression, supporting a biomarker-based strategy to target patients most likely to benefit.
• Outcomes were less favorable in patients with lower CD47 expression, pointing to a potential split in clinical benefit that could shape trial design and commercial positioning.
• Management scheduled a May 8 webcast tied to Q1 2026 results, with discussion of the breast cancer dataset and implications for ongoing development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ALX Oncology Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070800PRIMZONEFULLFEED9715013) on May 07, 2026, and is solely responsible for the information contained therein.